ArticleAnnals of surgical oncology2023
Targeted Axillary Dissection with
Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement.The British journal of surgery · 2024Pooled it
- Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysis.NPJ breast cancer · 2026Article
- Iodine seed-marking protocol for response-guided axillary de-escalation after neoadjuvant therapy in node-positive breast cancer.Translational cancer research · 2026Article
- Oncologic First Events in Breast Cancer Patients After Targeted Axillary Dissection.Annals of surgical oncology · 2025Article
- Reply to "Comment on TAD Outcomes from the Danish Breast Cancer Group Database".Annals of surgical oncology · 2025Article
- Peri-Lymph Node Tattooing with Carbon Nanoparticles Suspension: A Novel Strategy for Targeted Axillary Dissection in Breast Cancer.International journal of nanomedicine · 2025Article
- Review
- Assessing the Efficacy of Radioactive Iodine Seed Localisation in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy: A Systematic Review and Pooled Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis.Journal of clinical medicine · 2024Review
- Review
- ASO Author Reflections: Comparison of Two-Step Methods for Targeted Axillary Dissection in Denmark.Annals of surgical oncology · 2023Article
- Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial.World journal of surgical oncology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundTargeted axillary dissection (TAD), with marking of the metastatic lymph node before neoadjuvant chemotherapy (NACT), is increasingly used for breast cancer axillary staging. In the case of axillary pathological complete response (ax-pCR), axillary lymph node clearance can be omitted. Several marking methods exist, most using re-marking before surgery. Feasibility, learning curve, and identification rate (IR) vary. Marking with
methodsPatients staged with
results142 patients were included. The IR of the MLN was 99.3%, and the IR of the SLNB was 91.5%. TAD success was 91.5%. Minor challenges in marking or removal of the MLN were noted in three patients. In 72.3% of the patients, the MLN was a sentinel node. Overall, 40.8% had axillary pCR.
conclusionTAD with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.